In the ever-evolving landscape of healthcare, groundbreaking innovations are not merely celebrated for their scientific ...

Eli Lilly plans to launch Mounjaro, its blockbuster diabetes drug, in countries like China, India, Brazil and Mexico by 2026, ...

Eli Lilly’s rising fortunes tied to its weight loss and diabetes drugs led to a nine-figure payday for its top executive — and covered an exclusive trip for leaders to attend last summer’s ...

RiverPark Advisors, an investment advisory firm and sponsor of the RiverPark family of mutual funds, released its “RiverPark ...

Eli Lilly's latest clinical readout for dual GIP/GLP-1 agonist tirzepatide is a big one, with data suggesting the drug can reduce the risk of developing type 2 diabetes in overweight and obese ...

The lawmakers, led by Sen. Dick Durbin (D-Ill.) in October sent similar letters to Pfizer and Lilly demanding answers about their relationships with the telehealth prescribers, which patients can ...

"People come together, operators, with their supervisors at 6 a.m. every morning, and they talk about what issues they have and how they propose to solve it. Those get escalated through all levels of ...

A federal judge has effectively ended the ability of compounding pharmacies to make their own copies of Eli Lilly’s weight ...

Eli Lilly is just weeks away from launching Mounjaro in the UK, after getting approval from medicines regulator, the MHRA, for a new formulation of the drug as a treatment for diabetes and obesity.

Eli Lilly says a new trial showed the key ingredient in its popular drugs Zepbound and Mounjaro helped slash the chance of developing type 2 diabetes by 94% among patients at high risk.

Either Lilly or Novo could quickly develop one themselves if they thought there was genuine demand. For more context, auto-injectors are designed to deliver a pre-measured dose of a medication.